Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Chest. 2021 Jul;160(1):104-113. doi: 10.1016/j.chest.2021.03.024. Epub 2021 Mar 18.
Sex and gender differences in lung health and disease are imperative to consider and study if precision pulmonary medicine is to be achieved. The development of reliable COPD biomarkers has been elusive, and the translation of biomarkers to clinical care has been limited. Useful and effective biomarkers must be developed with attention to clinical heterogeneity of COPD; inherent heterogeneity exists related to grouping women and men together in the studies of COPD. Considering sex and gender differences and influences related to -omics may represent progress in susceptibility, diagnostic, prognostic, and therapeutic biomarker development and clinical innovation to improve the lung health of men and women.
如果要实现精准肺病医学，就必须考虑和研究肺部健康和疾病中的性别差异。可靠的 COPD 生物标志物的开发一直难以捉摸，生物标志物向临床护理的转化也受到限制。有用且有效的生物标志物必须在关注 COPD 临床异质性的情况下开发；由于在 COPD 的研究中，将女性和男性归为一组，因此存在与分组相关的固有异质性。考虑与组学相关的性别差异和影响因素，可能代表着在易感性、诊断、预后和治疗生物标志物开发以及临床创新方面的进展，从而改善男性和女性的肺部健康。
